Kinera’s lead therapeutic CMK103
is a recombinant human form of MK protein for use in cardiac ischemia (heart
attack). Treatment with CMK103 significantly enhances survival in
pre-clinical models of cardiac ischemia.
In pre-clinical animal studies, MK reduced infarct size by preventing apoptotic
death in heart muscle cells that had been cut-off from blood supply. MK treatment also prevented ventricular
remodelling and improved cardiac function in the weeks after infarction. No MK
toxicities have been observed in animal studies to date. Further pre-clinical
and manufacturing studies of CMK103 are currently underway.
Treatment with midkine significantly reduces mortality and
improves survival in preclinical models of myocardial infarction